Dr Reddy launches 'Doxobid' for Indian market

Mumbai, May 16: Dr Reddy's Laboratories Ltd has launched a European research product called doxofylline, a novel second-generation xanthine bronchodilator, in the Indian market for the first time.

In a release issued to the BSE today, the company informed that it has introduced this product under license agreement from Kent Union Ltd, Hong Kong and marketing cooperation with the Netherlands-based pharma company, Eurodrug Laboratories BV.

The product has been introduced under the brand name Doxobid and will be available in a special pack of 10s in 400 mg dosage. Doxobid is meant to treat patients suffering from asthma and COPD (Chronic Obstructive Pulmonary Disease).

Launched nationwide, doxobid is expected to help the company consolidate its position in the asthma and COPD segment, the release added.

UNI